CYRX : Summary for CryoPort, Inc. - Yahoo Finance

U.S. Markets close in 49 mins.

Cryoport, Inc. (CYRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.70+0.06 (+2.27%)
As of 2:47 PM EST. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.64
Bid2.69 x 100
Ask2.70 x 400
Day's Range2.63 - 2.73
52 Week Range1.03 - 3.00
Avg. Volume19,612
Market Cap47.52M
PE Ratio (TTM)-2.67
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube8 days ago

    ETFs with exposure to CryoPort, Inc. : December 1, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • CryoPort, Inc. :CYRX-US: Earnings Analysis: Q2, 2017 By the Numbers : November 30, 2016
    Capital Cube9 days ago

    CryoPort, Inc. :CYRX-US: Earnings Analysis: Q2, 2017 By the Numbers : November 30, 2016

    Categories: Yahoo Finance Get free summary analysis CryoPort, Inc. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of CryoPort, Inc. – General Finance Corporation and Wesco Aircraft Holdings, Inc (GFN-US and WAIR-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.98 million, ... Read more (Read more...)

  • Zacks Small Cap Research11 days ago

    CYRX: Record Revenue, Inching Closer To Supporting Commercialized Product

    Q2 revenue, at $2.0M, is up 38% yoy and inline with our $1.9M estimate.  It is also a new record and up 3% from fiscal Q1 2017.  Fueled by the consistent addition of new clients, greater overall utilization, progression of customers’ clinical trial programs and exponential growth of immunotherapy development, the biopharma segment continues to account for the vast majority of CYRX’s revenue and is driving most of the top-line growth.  Biopharma revenue grew almost 64% yoy and accounted for about 70% of total revenue.  With another 30 customers added during Q2 and expanding the number of clinical trials that CYRX is supporting to 100+ (from 90 as of August), including 16 phase III studies (up from 14 in August), the company continues to build a high-opportunity customer base.